V. Andrews

发表

Vasodilator and inotropic agents in treatment of chronic cardiac failure: clinical experience and response in exercise performance.

A. Fishman, J. S. Janicki, K. Weber, 1981, American heart journal.

Cardiotonic agents in the management of chronic cardiac failure.

J. S. Janicki, K. Weber, V. Andrews, 1982, American heart journal.

Milrinone in the treatment of chronic cardiac failure: a controlled trial.

J. S. Janicki, K. Weber, M. Rocci, 1985, American heart journal.

Pharmacokinetics and hemodynamics of amrinone in patients with chronic cardiac failure of diverse etiology.

K. Weber, M. Rocci, V. Andrews, 1987, Research communications in chemical pathology and pharmacology.

Amrinone in the treatment of chronic cardiac failure.

M. Sutton, J. S. Janicki, K. Weber, 1984, Journal of the American College of Cardiology.

Relationship between otoadmittance and threshold measurements in a TTS paradigm with phonation

Virginia Anathalie Taylor Andrews, V. Andrews, 1973 .

Advances in the evaluation and management of chronic cardiac failure.

J. S. Janicki, K. Weber, V. Andrews, 1984, Chest.

Amrinone and exercise performance in patients with chronic heart failure.

A. Fishman, J. S. Janicki, K. Weber, 1981, The American journal of cardiology.

Pirbuterol, An Oral Beta‐adrenergic Receptor Agonist, in the Treatment of Chronic Cardiac Failure

N. Reichek, J. S. Janicki, K. Weber, 1982, Circulation.

Eplerenone for chronic central serous chorioretinopathy in patients with active, previously untreated disease for more than 4 months (VICI): a randomised, double-blind, placebo-controlled trial

S. Harding, S. Sivaprasad, T. Peto, 2020, The Lancet.